British biotech Heptares snapped up by Japan’s Sosei in $400m deal

The Telegraph reports that the LMB spin-out company Heptares has been acquired by Japanese pharmaceutical company Soseito. The group’s research and development activities and 72 employees will remain in Hertfordshire, and Heptares will operate as an autonomous subsidiary to Sosei. Heptares is developing a string of drugs using a technology which can determine the precise shape of the target molecule, originally developed in the LMB. Its most advanced drug, which aims to treat Alzheimer’s, recently entered human trials. More…